One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL) deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib (IB). the first-in-class BTK inhibitor. and obinutuzumab-chlorambucil (G-CHL) are commonly used therapies for elderly and/or comorbid patients. https://unitedssports.shop/product-category/bike-parts-bmx-frames/